Qualification Type: | PhD |
---|---|
Location: | Swansea |
Funding for: | UK Students |
Funding amount: | £20,780 per annum |
Hours: | Full Time |
Placed On: | 16th July 2025 |
---|---|
Closes: | 11th August 2025 |
Reference: | RS862 |
Ovarian cancer is the deadliest of all gynaecological cancers (>2000 deaths/year, UK). It is described as a silent killer as most diagnoses occur after it has spread to the peritoneal cavity (metastasis). It is known that peritoneal cells contribute to the growth of metastatic tumours. Previously, it was demonstrated that an immune cell-produced metabolite promotes peritoneal tumour growth (https://doi.org/10.1172/jci99169). However, a host of interconnected metabolic and immune pathways likely regulate tumour progression.
Identification of these novel mechanisms will provide new targeted therapeutic strategies for ovarian cancer.
The current MRC New Investigator Grant focuses on peritoneal dialysis for kidney disease and aims to add metabolites/drugs to improve this treatment, but this also opens the exciting possibility for using peritoneal dialysis as a tissue-targeted drug delivery tool for metastatic ovarian cancer. This includes utilising existing chemotherapies (e.g. Carboplatin) and targeting new peritoneal-specific mechanisms that promote tumour growth.
This scholarship covers the full cost of tuition fees and an annual stipend at UKRI rate (currently £20,780 for 2025/26).
Additional research expenses of up to £1,000 per year will also be available.
Type / Role:
Subject Area(s):
Location(s):